Vidutolimod (CMP-001) is a TLR-9 agonist packaged within a virus-like particle that has been studied in combination with pembrolizumab as neoadjuvant therapy for fully resected stage III melanoma and advanced melanoma. This evidence concerns the gene TLR9 and melanoma.